2011 Progress Report

2011 Progress Report

Progress January – December Report 2011 Milwaukee Campus Minneapolis Campus Medical College of Wisconsin National Marrow Donor Program 9200 W Wisconsin Ave, Suite C5500 3001 Broadway St NE, Suite 110 Milwaukee WI 53226 USA Minneapolis MN 55413-1753 USA (414) 805-0700 (612) 884-8600 www.cibmtr.org Center for International Blood and Marrow Transplant Research Progress Report: January – December 2011 Table of Contents 1.0 OVERVIEW OF CIBMTR ......................................................................................................................................... 1 1.1 BACKGROUND .........................................................................................................................................1 1.2 ORGANIZATIONAL STRUCTURE ...............................................................................................................1 1.3 COMMITTEE STRUCTURE ........................................................................................................................3 1.4 CIBMTR STATISTICAL CENTER PERSONNEL .............................................................................................7 1.5 STAFF TRAINING AND ORGANIZATIONAL DEVELOPMENT ................................................................... 13 2.0 CIBMTR RESEARCH ACTIVITIES ........................................................................................................................... 16 2.1 OBSERVATIONAL RESEARCH ................................................................................................................. 16 2.2 CIBMTR STUDIES ................................................................................................................................... 17 2.3 CLINICAL TRIALS SUPPORT AND PROSPECTIVE RESEARCH................................................................... 17 2.4 IMMUNOBIOLOGY RESEARCH ACTIVITIES ............................................................................................ 19 2.5 HEALTH SERVICES RESEARCH (HSR) PROGRAM ................................................................................... 20 2.6 STEM CELL THERAPEUTIC OUTCOMES DATABASE (SCTOD) ................................................................. 21 2.7 CELLULAR THERAPY FOR REGENERATIVE MEDICINE (CTRM) ............................................................... 23 2.8 HCT FOR MYELODYSPLASTIC SYNDROME (MDS) FOR MEDICARE RECIPIENTS .................................... 23 2.9 DISEASE-BASED REGISTRY FOR SEVERE APLASTIC ANEMIA (SAA) ....................................................... 24 3.0 STATISTICAL RESOURCES .................................................................................................................................... 25 4.0 DATA COLLECTION, ACCRUAL, AND MANAGEMENT.......................................................................................... 26 4.1 TRANSPLANT DATA COLLECTION ......................................................................................................... 26 4.2 LEVELS OF DATA COLLECTION .............................................................................................................. 28 4.3 DATA MANAGEMENT ........................................................................................................................... 29 4.4 DATA QUALITY ...................................................................................................................................... 30 5.0 HUMAN SUBJECTS/HIPAA COMPLIANCE ............................................................................................................ 33 5.1 INSTITUTIONAL REVIEW BOARD APPROVALS ...................................................................................... 33 5.2 PRIVACY RULE – HIPAA ......................................................................................................................... 33 5.3 GENDER AND MINORITY INCLUSION .................................................................................................... 34 5.4 INCLUSION OF CHILDREN ..................................................................................................................... 34 6.0 CIBMTR INFORMATION TECHNOLOGY SERVICES ............................................................................................... 35 6.1 FORMSNET™2.0 .................................................................................................................................... 36 6.2 FORMSNETTM3.0 ................................................................................................................................... 36 6.3 A GROWABLE NETWORK INFORMATION SYSTEM (AGNIS) .................................................................. 37 6.4 RESEARCH DATABASE ........................................................................................................................... 38 6.5 WEB PRESENCE ..................................................................................................................................... 39 6.6 DELIVERING MEANINGFUL DATA ......................................................................................................... 41 6.7 IT SECURITY ........................................................................................................................................... 42 7.0 MEETINGS & PRESENTATIONS ............................................................................................................................ 43 7.1 MEETINGS ............................................................................................................................................. 43 7.2 NEWSLETTERS ....................................................................................................................................... 44 8.0 SIGNIFICANCE ..................................................................................................................................................... 45 9.0 WORKING COMMITTEE STUDIES ........................................................................................................................ 47 9.1 ACUTE LEUKEMIA WORKING COMMITTEE ........................................................................................... 47 9.2 AUTOIMMUNE DISEASES WORKING COMMITTEE ............................................................................... 55 9.3 CELLULAR THERAPIES WORKING COMMITTEE ..................................................................................... 57 9.4 CHRONIC LEUKEMIA WORKING COMMITTEE ...................................................................................... 59 9.5 DONOR HEALTH AND SAFETY WORKING COMMITTEE ........................................................................ 63 9.6 GRAFT SOURCES & MANIPULATION WORKING COMMITTEE .............................................................. 65 9.7 GRAFT-VERSUS-HOST DISEASE WORKING COMMITTEE ...................................................................... 73 9.8 HEALTH POLICY & PSYCHOSOCIAL ISSUES WORKING COMMITTEE ..................................................... 81 9.9 IMMUNE DEFICIENCIES & INBORN ERRORS OF METABOLISM WORKING COMMITTEE ..................... 87 9.10 IMMUNOBIOLOGY WORKING COMMITTEE ....................................................................................... 91 9.11 INFECTION & IMMUNE RECONSTITUTION WORKING COMMITTEE ................................................ 105 9.12 INTERNATIONAL STUDIES WORKING COMMITTEE .......................................................................... 109 9.13 LATE EFFECTS & QUALITY OF LIFE WORKING COMMITTEE .............................................................. 113 9.14 LYMPHOMA WORKING COMMITTEE ............................................................................................... 117 9.15 NON-MALIGNANT MARROW DISORDERS WORKING COMMITTEE ................................................. 125 9.16 PEDIATRIC CANCER WORKING COMMITTEE .................................................................................... 129 9.17 PLASMA CELL DISORDERS WORKING COMMITTEE .......................................................................... 133 9.18 REGIMEN-RELATED TOXICITY & SUPPORTIVE CARE WORKING COMMITTEE .................................. 141 9.19 SOLID TUMORS WORKING COMMITTEE .......................................................................................... 149 APPENDIX A1: CIBMTR INTERNATIONAL CENTERS ................................................................................................ 153 APPENDIX A2: CIBMTR U.S. CENTERS ..................................................................................................................... 163 APPENDIX B1: CIBMTR STATISTICAL CENTER ORGANIZATIONAL STRUCTURE – MILWAUKEE CAMPUS .............. 172 APPENDIX B2: CIBMTR STATISTICAL CENTER ORGANIZATIONAL STRUCTURE – MINNEAPOLIS CAMPUS ............ 173 APPENDIX C: WORKING COMMITTEE LEADERSHIP ................................................................................................ 174 APPENDIX D1: ADVISORY COMMITTEE .................................................................................................................. 179 APPENDIX D2: EXECUTIVE COMMITTEE ................................................................................................................. 181 APPENDIX D3: CONSUMER ADVOCACY COMMITTEE ............................................................................................. 182 APPENDIX E: NOMINATING COMMITTEE ..............................................................................................................

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    215 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us